Sustained Reductions in Hereditary Angioedema (HAE) Attack Rates Observed over 96 Weeks of Oral Berotralstat Treatment Regardless of Initial Response - 01/02/22
Doi : 10.1016/j.jaci.2021.12.543
H. James Wedner, MD, MD FAAAAI 1, Raffi Tachdjian, MD MPH FAAAAI 2, Timothy Craig, DO FAAAAI 3, Philip Collis, PhD 4, Bhavisha Desai, PharmD 4, Dianne Tomita, MPH 4, Teresa Caballero, MD PhD 5
1 Washington University School of Medicine
2 UCLA School of Medicine
3 Department of Medicine and Pediatrics, Penn State University
4 BioCryst Pharmaceuticals, Inc.
5 Hospital Universitario La Paz
490
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2021
Pubblicato da Elsevier Masson SAS.
Vol 149 - N° 2S
P. AB164 - febbraio 2022 Ritorno al numero
Articolo precedente
- Intestinal Barrier Dysfunction Accompanies Peanut Allergy In A Genetically-Susceptible Mouse Model And Identifies Angiopoietin-like 4 As A Biomarker
- Erin Steinbach, Johanna Smeekens, Satyaki Roy, Takahiko Toyonaga, Caleb Cornaby, Layna Perini, Ana Berglind, Michael Kulis, Edwin Kim, Martin Ferris, Terrence Furey, A. Wesley Burks, Shehzad Sheikh
- Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate
- Emel Aygoren-Pursun, Donald McNeil, Philip Collis, Bhavisha Desai, Dianne Tomita, Douglas Johnston
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?